INCREASED E-CADHERIN EXPRESSION OR ACTIVITY FOR THE TREATMENT OF INFLAMMATORY DISEASES
申请人:The Cleveland Clinic Foundation
公开号:US20220008402A1
公开(公告)日:2022-01-13
Provided herein are methods and systems employing agents that up-regulate E-cadherin, or E-cadherin agonists, for the treatment of inflammatory diseases, such as inflammatory bowel diseases (e.g., Crohn's disease). In certain embodiments, the agent employed is ML327, E-cadherin Up-regulator (ECU), or a compound of Formula I or II.